Xue Y, Guo Y, Xie X
Leukemia Research Unit, Jiangsu Institute of Hematology, Suzhou, People's Republic of China.
Leuk Res. 1997 Feb;21(2):107-9. doi: 10.1016/s0145-2126(96)00087-2.
The t(7;11)(p15;p15) translocation is an uncommon balanced aberration which has been found predominantly in Orientals, frequently presenting as de novo acute myeloid leukemia (AML) and occasionally as chronic myeloid leukemia in blastic crisis. This paper reports the first case of therapy-related AML (t-AML) with t(7;11). The patient was a 36-year-old Chinese man with a longstanding psoriasis for which he had received bimolane and ICRF-154 therapy. His cytology and cytochemistry were compatible with M2 subtype of AML. He achieved a complete remission after two courses of HA regimen (homoharringtonine and Ara-c). Six months later, he relapsed and died of overwhelming infection after 3 months. Chromosome analysis on bone marrow cells using short-term culture and R-banding at presentation revealed his karyotype to be 46,XY,t(7;11)(p15;p15)/ 46,XY,t(7;11)(p15;p15),del(12)(p12)/ 46,XY. This case implies: (1) dioxopiperazine derivatives can induce AML with t(7;11) in addition to inducing AML with t(15;17) or t(8;21); (2) t(7;11) may be found not only in de novo AML, but also in t-AML. Chromosomal translocation t(7;11) should be added to t(8;21), t(15;17) and inv(16) as favourable cytogenetic abnormalities associated with t-AML.
t(7;11)(p15;p15)易位是一种罕见的平衡畸变，主要在东方人中发现，常表现为原发性急性髓系白血病（AML），偶尔也表现为慢性髓系白血病急变期。本文报道了首例伴有t(7;11)的治疗相关AML（t-AML）病例。患者为一名36岁的中国男性，患有长期银屑病，曾接受乙双吗啉和ICRF-154治疗。其细胞学和细胞化学检查结果与AML的M2亚型相符。经过两个疗程的HA方案（高三尖杉酯碱和阿糖胞苷）治疗后，他达到了完全缓解。6个月后，他复发，并在3个月后死于严重感染。就诊时采用短期培养和R显带技术对骨髓细胞进行染色体分析，结果显示其核型为46,XY,t(7;11)(p15;p15)/46,XY,t(7;11)(p15;p15),del(12)(p12)/46,XY。该病例提示：（1）二氧哌嗪衍生物除了可诱导伴有t(15;17)或t(8;21)的AML外，还可诱导伴有t(7;11)的AML；（2）t(7;11)不仅可在原发性AML中发现，也可在t-AML中发现。染色体易位t(7;11)应作为与t-AML相关的有利细胞遗传学异常，添加到t(8;21)、t(15;17)和inv(16)中。
